CD163 and neoplasm: CD162 (PSGL-1) is a pro-atherogenic marker as it binds platelets, CD163 is a marker of tumor-supporting macrophages, CD169 defines tolerogenic (anti-inflammatory) monocytes binding to red cells, CD97 is an EGF-TM7 receptor, and pattern-recognition-receptor CD204 engagement is pro-inflammatory.